Format

Send to

Choose Destination
Bull Math Biol. 2018 Feb 8. doi: 10.1007/s11538-018-0402-x. [Epub ahead of print]

Micropharmacology: An In Silico Approach for Assessing Drug Efficacy Within a Tumor Tissue.

Author information

1
Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
2
Integrated Mathematical Oncology Department, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. kasia@rejniak.net.
3
Department of Oncologic Sciences, Morsani College of Medicine, University of South Florida, Tampa, FL, USA. kasia@rejniak.net.

Abstract

Systemic chemotherapy is one of the main anticancer treatments used for most kinds of clinically diagnosed tumors. However, the efficacy of these drugs can be hampered by the physical attributes of the tumor tissue, such as tortuous vasculature, dense and fibrous extracellular matrix, irregular cellular architecture, tumor metabolic gradients, and non-uniform expression of the cell membrane receptors. This can impede the transport of therapeutic agents to tumor cells in sufficient quantities. In addition, tumor microenvironments undergo dynamic spatio-temporal changes during tumor progression and treatment, which can also obstruct drug efficacy. To examine ways to improve drug delivery on a cell-to-tissue scale (single-cell pharmacology), we developed the microscale pharmacokinetics/pharmacodynamics (microPKPD) modeling framework. Our model is modular and can be adjusted to include only the mathematical equations that are crucial for a biological problem under consideration. This modularity makes the model applicable to a broad range of pharmacological cases. As an illustration, we present two specific applications of the microPKPD methodology that help to identify optimal drug properties. The hypoxia-activated drugs example uses continuous drug concentrations, diffusive-advective transport through the tumor interstitium, and passive transmembrane drug uptake. The targeted therapy example represents drug molecules as discrete particles that move by diffusion and actively bind to cell receptors. The proposed modeling approach takes into account the explicit tumor tissue morphology, its metabolic landscape and/or specific receptor distribution. All these tumor attributes can be assessed from patients' diagnostic biopsies; thus, the proposed methodology can be developed into a tool suitable for personalized medicine, such as neoadjuvant chemotherapy.

KEYWORDS:

Drug penetration; Hypoxia-activated pro-drugs; Single-cell pharmacology; Targeted therapeutics; Tumor tissue architecture; microPKPD

PMID:
29423880
PMCID:
PMC6082744
[Available on 2019-08-08]
DOI:
10.1007/s11538-018-0402-x

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center